Area of research
Epidemiology · Oncology
Research interest
Research interests include Cytomegalovirus and herpesvirus research, CAR-T cell therapy research, Viral-associated cancers and disorders, and Herpesvirus Infections and Treatments.
Establishing Permanence, Not Patchwork: Sustaining Coordinated Research Networks for Immunocompromised Populations.
Assessing VirScan serosurvey epitope profiling variability between in-clinic venous blood draw and capillary blood self-sampling device.
First report on remdesivir use for the treatment of respiratory syncytial virus in five allogeneic hematopoietic cell transplant recipients.
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.
Noncanonical and mortality-defining toxicities of CAR T cell therapy
Association of CD19<sup>+</sup>-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality.
T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy.
ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients.
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.
Noncanonical and mortality-defining toxicities of CAR T cell therapy.
The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy.
Distinct Patterns of Pathogen-Specific and Non-Specific Immune Reconstitution after CD19/20- Versus BCMA-Targeted CAR-T Cell Therapy
A Network for Advancing Prevention and Treatment of Infections Among Immunocompromised Individuals.
Cytomegalovirus Viral Load Continues to Predict Poor Outcomes in Adults and Children Despite Improved Hematopoietic Cell Transplantation Success.
Influence of B cell or plasma cell-targeted CAR-T cell therapy on humoral immunity and vaccine immunogenicity: The HICAR study
The iciHHV-6 Sense: Sensing the Source and Relevance of Human Herpesvirus 6 (HHV-6) DNA in the Transplant Recipient With Inherited Chromosomally Integrated HHV-6.
Endogenous human herpesviruses 6A/B.
American Society for Transplantation and Cellular Therapy Series #9: Management of Human Herpesvirus 6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T-Cell Therapy.
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy.
Delayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults.
Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study.
Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Serial Quantitation of Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive Mold Infections After Hematopoietic Cell Transplant.
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape.
How Immunocompromised Hosts Were Left Behind in the Quest to Control the COVID-19 Pandemic.